Sugi Predict

Sugi Predict / Compounds / SCHEMBL908949

SCHEMBL908949

SCHEMBL908949

COc1nc(Cl)ccc1[N+](=O)[O-]

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MERTK Q12866 1/20 0.72
▸ MAPT P10636 4/20 0.44
▸ HTT P42858 3/20 0.44
▸ PIN1 Q13526 2/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ S1PR4 O95977 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ TXNRD1 Q16881 8/20 0.43
▸ GSR P00390 4/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ TDP1 Q9NUW8 2/20 0.42
▸ POLB P06746 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29364631 1.00 MERTK (0.72) MERTKMAPTHTTPIN1JAK2
SCHEMBL21436737 0.82 MERTK (0.51) MERTKMAPTHTTPIN1JAK2
SCHEMBL10696793 0.81 MERTK (0.58) MERTKMAPTHTTPIN1S1PR4
SCHEMBL29364572 0.81 MERTK (0.58) MERTKMAPTHTTPIN1JAK2
SCHEMBL4652565 0.81 MERTK (0.58) MERTKMAPTHTTPIN1JAK2
SCHEMBL16931267 0.81 MERTK (0.58) MERTKMAPTHTTPIN1S1PR4
SCHEMBL29361819 0.81 MERTK (0.58) MERTKMAPTHTTPIN1S1PR4
SCHEMBL15514986 0.80 MERTK (0.49) MERTKMAPTHTTS1PR4S1PR1
SCHEMBL10740434 0.80 TXNRD1 (0.58) MAPTHTTJAK2S1PR4HSP90AA1
SCHEMBL29983153 0.80 MERTK (0.49) MERTKMAPTHTTS1PR4S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099466-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2026-05-15 — — WO disclosed
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 — — US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 — — US disclosed
US-12448368-B2 Indole compounds as androgen receptor modulators NIDO BIOSCIENCES, INC. (US) 2025-10-21 — — US disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 — — US disclosed
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 — — US disclosed
US-20250122176-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES INC (US) 2025-04-17 — — US disclosed
US-20250092021-A9 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2025-03-20 — — US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 — — WO disclosed
WO-2025024521-A1 SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS, INC. (US) 2025-01-30 — — WO disclosed
US-6306840-B1 ANTISTICKING AGENTS OF OLIGOPEPTIDES BIOGEN, INC. 2001-10-23 — — US disclosed
EP-1142867-A2 Cell adhesion inhibitors BIOGEN, INC. (US) 2001-10-10 — — EP disclosed
US-6248713-B1 OLIGOPEPTIDE FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BIOGEN, INC. 2001-06-19 — — US disclosed
US-6239108-B1 Cell adhesion inhibitors BIOGEN, INC. 2001-05-29 — — US disclosed
EP-1087963-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 Chiron Corporation (US) 2001-04-04 — — EP disclosed
WO-1999065897-A1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 1999-12-23 — — WO disclosed
EP-0842196-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1998-05-20 — — EP disclosed
EP-0805796-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-11-12 — — EP disclosed
WO-1997003094-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-01-30 — — WO disclosed
WO-1996022966-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1996-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243180-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MERTK 238/4885MAPT 389/4885HTT 406/4885
US-12459920-B2 Targeted protein degradation NEK7, NEK1, RIPK1 MERTK 243/4885MAPT 383/4885HTT 406/4885
US-20250122176-A1 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 MERTK 4855/4885MAPT 735/4885HTT 397/4885
US-20250092021-A9 INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 MERTK 4855/4885MAPT 735/4885HTT 397/4885
US-12448368-B2 Indole compounds as androgen receptor modulators AR, FSHR, ADRB3 MERTK 4849/4885MAPT 682/4885HTT 278/4885
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR MERTK 2980/4885MAPT 3496/4885HTT 163/4885
US-20250340528-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MERTK 238/4885MAPT 389/4885HTT 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.